OSAKA, Japan & CAMBRIDGE, Mass - Monday, 21. November 2022
- The PhALLCON Study Is the First Global, Phase 3, Registrational, and Only Head-To-Head Clinical Trial Comparing Two TKIs in Frontline Ph+ ALL
- Primary Endpoint Result Shows Superiority Compared to Imatinib as Assessed by MRD-Negative Complete Remission
(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with ICLUSIG® (ponatinib) plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease (MRD)-negative complete remission (CR) compared to imatinib. MRD-negativity is associated with improvement in long-term outcomes for patients, as reported in literature. ICLUSIG is the only pan-mutational and third-generation tyrosine kinase inhibitor (TKI), targeting BCR:
...
Read more »
|
(BUSINESS WIRE)--Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, announced the opening of its Asia Pacific, Middle East and Africa (APMEA) Strategic Market Unit Headquarters in Dubai, UAE.
His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai and Chairman of The Executive Council of Dubai, and His Highness Sheikh Maktoum bin Mohammed bin Rashid Al Maktoum, Deputy Ruler of Dubai, and Deputy Prime Minister and Minister of Finance of the UAE, along with prominent UAE officials, visited the newly opened headquarters on its inaugural day.
His Highness Sheikh Hamdan bin Mohammed said, “The establishment of Wipro’s new facility in Dubai reflects the emirate’s growing profile as a global hub for the world’s leading information technology companies. Vice President and Prime Minister of the UAE and Ruler of Dubai His Highness Sheikh Mohammed bin Rashid Al Maktoum&rs
...
Read more »
|
PHILADELPHIA - Thursday, 17. November 2022 AETOSWire
(BUSINESS WIRE)--Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by nerve injuries, announced the appointment of industry R&D pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D. to the company’s Board of Directors.
“On behalf of the Neuraptive Board and its directors, we are excited to welcome Bob to the board,” said Robert Radie, chairman, and chief executive officer of Neuraptive. “His extensive experience in drug research and development is a great addition to the Neuraptive board at this important time. We are fortunate to have attracted such an accomplished leader in our industry which speaks to the promise and potential of the work we are doing to transform the treatment of peripheral nerve injuries."
Dr. Ruffolo has over 40 years of research an
...
Read more »
|
LONDON - Saturday, 19. November 2022 AETOSWire
- Specialisms now include supporting clients with the Climate Transition
- Agency now has seven offices globally across three continents
- Reflects changing needs of the industry, clients and employees
(BUSINESS WIRE)--Cognito, the independent global communications agency, has today announced the launch of its new brand identity. Five years on from the last refresh, the new look and positioning reflects the agency’s growth and expansion across service lines, sectors and geographies to meet the needs of its global client roster. The agency’s client base comprises over 100 firms in finance, technology and professional services from the largest and best-known brands in the industry to dynamic start and scale ups.
The new brand design reflects the agency’s unique approach to solving business challenges, commitment to innovation and bringing new thinking and ideas to clients and
...
Read more »
|
Wolters Kluwer Health will serve as the exclusive digital distributor of subscriptions to the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst and NEJM Journal Watch for research and medical institutions across the globe
(BUSINESS WIRE) -- Wolters Kluwer Health and NEJM Group have entered into an exclusive partnership to ensure that more researchers and clinicians around the world can access the growing family of NEJM Group journals. Building on years of collaboration, this expanded partnership positions NEJM Group journals for sustained global growth through Wolters Kluwer’s Ovid® medical research platform. Publications currently included are the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst Innovations in Care Delivery, NEJM Journal Watch, the NEJM Archive, and future NEJM Group journals.
Unparalleled distribution critical to global reach
“The mission of NEJM Group is to advance medical knowledge from research to
...
Read more »
| |